Economic analysis of the Confronting COPD survey: An overview of results

Respiratory Medicine

Volumn 97, Issue SUPPL. C, 2003, Pages

  Wouters, Emiel F M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic obstructive pulmonary disease; COPD; Direct costs; Healthcare resource; Indirect costs; Societal costs

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; THEOPHYLLINE;

ADULT; ARTICLE; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; COST OF ILLNESS; DATA ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; ECONOMIC ASPECT; FEMALE; FRANCE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH PRACTITIONER; HEALTH SURVEY; HOSPITALIZATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PATIENT CARE; PRIORITY JOURNAL; PRODUCTIVITY; SOCIETY; SPAIN; UNITED KINGDOM; UNITED STATES;

ABSENTEEISM; AGED; AGED, 80 AND OVER; COST OF ILLNESS; EUROPE; FEMALE; HEALTH CARE COSTS; HEALTH CARE SURVEYS; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; PATIENT COMPLIANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM AGENTS;

EID: 0037372035     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(03)80020-3     Document Type: Article

References (26)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Executive Summary. NHLBI/WHO Workshop Report 2001.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
3. Soriano JB, Maier WC, Egger P, et al. Recent trends in physician diagnosed COPD in men and women in the U.K. Thorax 2000; 55: 789-794.
4. Vermeire P. The burden of chronic obstructive pulmonary disease. Respir Med 2002; 96: S3-S10.
5. Chapman KR, Bourbeau J, Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C); S23-S31.
6. Piperno D, Huchon G, Pribil C, Boucot I, Smilowski T. The burden of COPD in France: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C); S33-S42.
7. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C); S43-S50.
8. Wouters EFM. The burden of COPD in the Netherlands: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C); S51-S59.
9. Izquierdo JL. The burden of COPD in Spain: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C);S61-S69.
10. Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C); S71-S79.
11. Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C); S81-S89.
12. Halpern MT, Musin A, Sondhi S. Economic analysis of the Confronting COPD survey: methodology. Respir Med 2003; 97(Suppl C): S15-S22.
13. Rennard S, Decramer M. Calverley PMA et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002; 20: 799-805.
14. GNP PPPs 1997: http://www.oecd.org/EN/statistics/0,,EN-statistics- 0-nodirectorate-no-no-no-0,00.html
15. Rutten-van Mölken MPMH, van Doorslaer EKA, Till MD. Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. Pharmocoeconomics 1998; 14: 671-684.
16. British Thoracic Society/MORI. The Burden of Lung Disease Survey 2002. http://www.brit-thoracic.org.uk
17. Buist S. Guidelines for the management of chronic obstructive pulmonary disease. Respir Med 2002; 96: S11-S16.
18. Price MJ, Hurrell C, Efthimiou J, Medley HV. Health care costs of treating exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 30s.
19. Pride NB, Smoking cessation: effects on symptoms, spirometry and future trends in COPD. Thorax 2001; 56(Suppl 2): ii7-ii10.
20. Feenstra TL, van Genugten MLL, Hoogenveen RT, Wouters EF, Rutten-van Mölken MPMH.The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease. A model analysis in the Netherlands. Am J Respir Crit Care Med 2001; 164: 590-596.
21. Halpern MT Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993; 85:457-464;
22. Garfinkel L, Stellman SD. Mortality by relative weight and exercise. Cancer 1988; 62(Suppl): 1844-1850.
23. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The costs of treating COPD in the United States. Chest 2001; 119: 344-352.
24. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease. Arch Intern Med 2000; 160: 2653-2658.
25. Jones PW, Wilson K, Sondhi S. Economic evaluation of salmeterol xinafoate in chronic obstructive pulmonary disease (COPD): demonstrating improved outcomes and health status. Eur Respir J 2000; 16: 56s.
26. Howard K, McLaughlin T, Pathak D et al. A cost analysis of salmeterol xinafoate (Serevent®) versus ipratropium bromide (Atrovent®) for the treatment of COPD. Am J Respir Crit Care Med